Cybin Archives

Psychedelics News

Cybin

Breaking News

19 Feb 2026

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

By Madison Roberts

Industry

6 Dec 2023

Cybin Granted U.S. Patent For CYB003 Psilocybin Program

New patent provides IP protection until at least 2041. Cybin’s patent portfolio now includes 39 granted patents and over 170 pending applications....

By Microdose NewsDesk

Breaking News

30 Nov 2023

Cybin Reports Positive Topline Data from Phase 2 Study of Major Depressive Disorder

Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses....

By Microdose NewsDesk

Breaking News

31 Oct 2023

Cybin Announces Positive Phase 2 Data for Phase 2 Depression Trial

This morning we received interim results on Cybin’s Phase 2 trial using its CYB003 psilocybin compound for depression. And they did not disappoint....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Finance

13 Oct 2023

Cybin Shareholders Approve Acquisition of Small Pharma

Cybin shareholders approve the acquisition of Small Pharma with 99.4% of the vote....

By Microdose NewsDesk

Industry

22 Sep 2023

Cybin Completes Phase 2 Enrollment of CYB003 for Major Depressive Disorder

Cybin moves its lead program forward as it completes enrollment of its Phase 2 study of major depressive disorder....

By Microdose NewsDesk

Finance

18 Sep 2023

Billionaire Investor Steve Cohen Buys 19 million Shares of Cybin

Renowned billionaire investor Steve Cohen has purchased almost 19 million shares of Cybin....

By Jason Najum

Industry

5 Sep 2023

Cybin Granted U.S. Patent for 5-MeO-DMT

The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine (5-MeO-DMT) analogs....

By Microdose NewsDesk

Breaking News

28 Aug 2023

Breaking News: Cybin to Acquire Small Pharma

In big breaking news, Cybin has signed a deal to acquire Small Pharma, giving Cybin an advanced DMT trial....

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result